NATCOPHARMNSENATCO PHARMA LTD.· PharmaceuticalsHighNeutral
Announced Tue, 14 Jul · 11:54 IST

NATCO Pharma raises Adcock Ingram stake to 49% via 13.25% acquisition

Listed Co AcquisitionStrategic Transactions View source PDF

NATCOPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.0%1-day move
₹979.55
prior close
₹969.15
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.2-0.2-0.2-1.0-1.5-3.6-2.8-1.9-5.8
Up moveDown movePending
AI summary

NATCO Pharma completed acquisition of an additional 13.25% stake in South Africa's Adcock Ingram Holdings, raising its shareholding from 35.75% to 49%. The deal was worth around ZAR 1.81 billion (about ₹1,060 crores), executed through NATCO's South African subsidiary. Adcock Ingram is the second largest pharma company in South Africa's private and public market with a 10% private market share. The move is part of NATCO's long-term Africa growth strategy, building on its 2025 delisting participation.

Likely market impact

Shareholders gain near-majority control in a key South African pharma asset, strengthening NATCO's Africa presence and potential for consolidated earnings.